DOCSLIB.ORG

The Role of Tetraspanin 6 in Colorectal Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Role of Tetraspanin 6 in Colorectal Cancer THE ROLE OF TETRASPANIN 6 IN COLORECTAL CANCER by Regina Andrijes A thesis submitted to the University of Birmingham for the degree of DOCTOR OF PHILOSOPHY Institute of Cancer and Genomics College of Medical and Dental Sciences University of Birmingham October 2018 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Colorectal cancer is one of the most common cancer types and the second leading cause of cancer-related deaths worldwide. Poor survival of patients highlights the importance of identification of novel prognostic markers. The work in this thesis presents Tspan6 as a potential candidate. Tspan6 is a poorly studied member of the tetraspanin family of proteins that has been implicated in cancer initiation, progression and metastasis. The expression of Tspan6 in a cohort of genetically profiled colorectal adenocarcinomas in this study demonstrated that Tspan6 expression is significantly reduced in tumours vs. adjacent non-cancerous tissues. To illustrate the role of Tspan6 in colorectal cancer (CRC) Tspan6 KO mice carrying APCmin/+ allele were generated. It was found that loss of Tspan6 gene accentuates APC-driven tumorigenesis in vivo. Specifically, these animals developed larger numbers of intestinal and colonic polyps. Interestingly, these polyps were significantly bigger in size and presented with a more severe neoplastic phenotype. The RNAseq analysis of polyps derived from APCmin/+ and APCmin/+Tspan6 KO showed substantial enrichment of differentially expressed genes within the MAPK signalling pathway. Additionally, our experiments with intestinal organoids derived from Tspan6 KO mice and a Caco-2 CRC cell model confirmed the important role of Tspan6 in EGFR-dependent signalling in colonic epithelium via a pathway involving autocrine production of TGF-α. Furthermore, it was demonstrated that Tspan6 regulates the production of EVs through the involvement of an adapter protein syntenin-1, an established partner of Tspan6 which is known to play a critical role in biogenesis of multivesicular bodies (MVBs) and exosomal production. Therefore, it is hypothesised that the Tspan6-syntenin-1 complex plays a critical role in suppressing of colorectal tumorigenesis by controlling autocrine secretion of EGFR ligands via i extracellular vesicles. The better understanding of the Tspan6-dependent mechanisms of EGFR regulation can underpin further development of EGFR- targeting therapy and improve survival of CRC patients. ii I dedicate this thesis to my mother, Luiza, and my siblings, Viorika and Artjom, who always love, understand and support me. ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS This PhD is undoubtedly one of the biggest achievements in my life. The whole journey has been a mixture of failure and success, excitement and frustration, discouragement and motivation, but overall very rewarding in my life. I would like to thank everyone who has helped me on the way. Firstly, I would like to express my gratitude to my PhD supervisors, Dr Fedor Berditchevski, Dr Andrew Beggs and Dr Chris Tselepis for the advice, guidance, constructive criticism, your help, support and encouragement. A special thank you to Dr Rahul Hejmadi and my friend and colleague Dr Maha Ibrahim for helping me with pathology examination and scoring of samples. I am grateful to Celina Whalley for helping me with RNA sequencing and all the members of Beggs lab for being helpful, kind and friendly. A special thank you to Richard Horniblow for consulting me, willingness to proof read countless pages of my reports and thesis and becoming a good friend in the process. I would like to thank all the staff, colleagues and fellow students of the Institute of Cancer and Genomics, you all have made this place a second home to me. I am also thankful to all the members of our laboratory, Maryam, Jing, and especially Isaac. Thank you for the stimulating discussions, for all the long hours we shared in the lab and the fun we had outside the lab, I could not ask for a better team to work with. I wish to express my eternal gratitude to Vera Novitskaia for always being there for me, for teaching, advising and listening. You have become my dearest friend, a shoulder to cry on, you have provided me with strength and motivation and taught me invaluable life lessons. I would like to thank all my friends in the UK and in Estonia for your unconditional friendship. Especially to my best friend Kristina, who iv ACKNOWLEDGEMENTS has shared with me the moments of happiness, when I was accepted to the program, the moments of frustration, when I was writing my thesis, and been there for me for over 18 years of my life. I would also like to express my gratitude, appreciation and love to Andrea for believing in me, supporting me and making me happy. And finally, I would like to thank my whole family: my mother, sister and brother for supporting me not only during my PhD but throughout my life. I would not be here if it was not for you. v TABLE OF CONTENTS TABLE OF CONTENTS ABSTRACT ................................................................................................................................. I ACKNOWLEDGEMENTS ......................................................................................................... IV TABLE OF CONTENTS ............................................................................................................ VI LIST OF FIGURES .................................................................................................................... XI LIST OF TABLES .................................................................................................................... XV ABBREVIATIONS ................................................................................................................... XVI 1 INTRODUCTION ............................................................................................................... 1 1.1 COLORECTAL CANCER ..................................................................................................... 1 1.1.1 Definition ............................................................................................................... 1 1.1.2 Types of cancers in the colon and rectum ............................................................ 1 1.1.3 Colorectal cancer incidence ................................................................................. 2 1.1.4 Colorectal cancer mortality and survival ............................................................... 2 1.1.5 The worldwide distribution of colorectal cancer .................................................... 3 1.1.6 Colorectal cancer risk factors ............................................................................... 5 1.1.7 Treatment of colorectal cancer ............................................................................. 9 1.2 MOLECULAR BASIS OF CRC ........................................................................................... 11 1.2.1 The anatomical structure of the colon ................................................................ 11 1.2.2 Molecular pathways of colorectal carcinogenesis .............................................. 14 1.2.3 Adenoma-Carcinoma sequence ......................................................................... 15 1.2.4 Serrated Pathway ............................................................................................... 17 1.3 SIGNAL TRANSDUCTION PATHWAYS IN COLORECTAL CANCER ........................................... 20 1.3.1 Wnt signalling ..................................................................................................... 20 1.3.2 EGFR signalling in colorectal cancer.................................................................. 27 1.4 MOUSE MODELS OF CRC ............................................................................................... 33 1.5 ORGANOIDS AS A MODEL OF COLORECTAL CANCER AND NORMAL INTESTINAL EPITHELIUM .. 41 1.6 TETRASPANINS .............................................................................................................. 45 vi TABLE OF CONTENTS 1.6.1 Overview ............................................................................................................. 45 1.6.2 Tetraspanin structure .......................................................................................... 45 1.6.3 Tetraspanin function ........................................................................................... 48 1.6.4 Tetraspanins and colorectal cancer.................................................................... 54 1.6.5 Tetraspanin 6 ...................................................................................................... 54 1.6.6 Tetraspanins, extracellular vesicles and exosomes ........................................... 59 1.7 RESEARCH OBJECTIVES ................................................................................................. 65 1.7.1 Aims ...................................................................................................................
Load more

Recommended publications
  • T2 and T17 Cytokines Alter the Cargo and Function of Airway Epithelium
    Ax et al. Respiratory Research (2020) 21:155 https://doi.org/10.1186/s12931-020-01402-3 RESEARCH Open Access T2 and T17 cytokines alter the cargo and function of airway epithelium-derived extracellular vesicles Elisabeth Ax1,2 , Zala Jevnikar2, Aleksander Cvjetkovic1 , Carina Malmhäll1 , Henric Olsson2, Madeleine Rådinger1*† and Cecilia Lässer1*† Abstract Background: Asthma is a common and heterogeneous disease that includes subgroups characterized by type 2 (T2) or type 17 (T17) immune responses for which there is a need to identify the underlying mechanisms and biomarkers in order to develop specific therapies. These subgroups can be defined by airway epithelium gene signatures and the airway epithelium has also been implicated to play a significant role in asthma pathology. Extracellular vesicles (EVs) carry functional biomolecules and participate in cell-to-cell communication in both health and disease, properties that are likely to be involved in airway diseases such as asthma. The aim of this study was to identify stimulus-specific proteins and functionality of bronchial epithelium-derived EVs following stimulation with T2 or T17 cytokines. Methods: EVs from cytokine-stimulated (T2: IL-4 + IL-13 or T17: IL-17A + TNFα) human bronchial epithelial cells cultured at air-liquid interface (HBEC-ALI) were isolated by density cushion centrifugation and size exclusion chromatography and characterized with Western blotting and electron microscopy. Transcriptomic (cells) and proteomic (EVs) profiling was also performed. Results: Our data shows that EVs are secreted and can be isolated from the apical side of HBEC-ALI and that cytokine stimulation increases EV release. Genes upregulated in cells stimulated with T2 or T17 cytokines were increased also on protein level in the EVs.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Viewed Under 23 (B) Or 203 (C) fi M M Male Cko Mice, and Largely Unaffected Magni Cation; Scale Bars, 500 M (B) and 50 M (C)
    BRIEF COMMUNICATION www.jasn.org Renal Fanconi Syndrome and Hypophosphatemic Rickets in the Absence of Xenotropic and Polytropic Retroviral Receptor in the Nephron Camille Ansermet,* Matthias B. Moor,* Gabriel Centeno,* Muriel Auberson,* † † ‡ Dorothy Zhang Hu, Roland Baron, Svetlana Nikolaeva,* Barbara Haenzi,* | Natalya Katanaeva,* Ivan Gautschi,* Vladimir Katanaev,*§ Samuel Rotman, Robert Koesters,¶ †† Laurent Schild,* Sylvain Pradervand,** Olivier Bonny,* and Dmitri Firsov* BRIEF COMMUNICATION *Department of Pharmacology and Toxicology and **Genomic Technologies Facility, University of Lausanne, Lausanne, Switzerland; †Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts; ‡Institute of Evolutionary Physiology and Biochemistry, St. Petersburg, Russia; §School of Biomedicine, Far Eastern Federal University, Vladivostok, Russia; |Services of Pathology and ††Nephrology, Department of Medicine, University Hospital of Lausanne, Lausanne, Switzerland; and ¶Université Pierre et Marie Curie, Paris, France ABSTRACT Tight control of extracellular and intracellular inorganic phosphate (Pi) levels is crit- leaves.4 Most recently, Legati et al. have ical to most biochemical and physiologic processes. Urinary Pi is freely filtered at the shown an association between genetic kidney glomerulus and is reabsorbed in the renal tubule by the action of the apical polymorphisms in Xpr1 and primary fa- sodium-dependent phosphate transporters, NaPi-IIa/NaPi-IIc/Pit2. However, the milial brain calcification disorder.5 How- molecular identity of the protein(s) participating in the basolateral Pi efflux remains ever, the role of XPR1 in the maintenance unknown. Evidence has suggested that xenotropic and polytropic retroviral recep- of Pi homeostasis remains unknown. Here, tor 1 (XPR1) might be involved in this process. Here, we show that conditional in- we addressed this issue in mice deficient for activation of Xpr1 in the renal tubule in mice resulted in impaired renal Pi Xpr1 in the nephron.
    [Show full text]
  • Differential Expression of Two Neuronal Intermediate-Filament Proteins, Peripherin and the Low-Molecular-Mass Neurofilament Prot
    The Journal of Neuroscience, March 1990, fO(3): 764-764 Differential Expression of Two Neuronal Intermediate-Filament Proteins, Peripherin and the Low-Molecular-Mass Neurofilament Protein (NF-L), During the Development of the Rat Michel Escurat,’ Karima Djabali,’ Madeleine Gumpel,2 Franqois Gras,’ and Marie-Madeleine Portier’ lCollBne de France, Biochimie Cellulaire, 75231 Paris Cedex 05, France, *HBpital de la Salpktricke, Unite INSERM 134, 75651Paris Cedex 13, France The expression of peripherin, an intermediate filament pro- and Freeman, 1978), now more generally referred to respectively tein, had been shown by biochemical methods to be local- as high-, middle-, and low-molecular-mass NFP (NF-H, NF-M, ized in the neurons of the PNS. Using immunohistochemical and NF-L). These proteins are expressed in most mature neu- methods, we analyzed this expression more extensively dur- ronal populations belonging either to the CNS or to the PNS; ing the development of the rat and compared it with that of developing neurons generally do not express any of them until the low-molecular-mass neurofilament protein (NF-L), which they become postmitotic (Tapscott et al., 198 la). is expressed in every neuron of the CNS and PNS. We, however, described another IFP with a molecular weight The immunoreactivity of NF-L is first apparent at the 25 of about 57 kDa, which we had first observed in mouse neu- somite stage (about 11 d) in the ventral horn of the spinal roblastoma cell lines and which was also expressed in rat pheo- medulla and in the posterior part of the rhombencephalon. chromocytoma PC1 2 cell line.
    [Show full text]
  • Absence of NEFL in Patient-Specific Neurons in Early-Onset Charcot-Marie-Tooth Neuropathy Markus T
    ARTICLE OPEN ACCESS Absence of NEFL in patient-specific neurons in early-onset Charcot-Marie-Tooth neuropathy Markus T. Sainio, MSc, Emil Ylikallio, MD, PhD, Laura M¨aenp¨a¨a, MSc, Jenni Lahtela, PhD, Pirkko Mattila, PhD, Correspondence Mari Auranen, MD, PhD, Johanna Palmio, MD, PhD, and Henna Tyynismaa, PhD Dr. Tyynismaa [email protected] Neurol Genet 2018;4:e244. doi:10.1212/NXG.0000000000000244 Abstract Objective We used patient-specific neuronal cultures to characterize the molecular genetic mechanism of recessive nonsense mutations in neurofilament light (NEFL) underlying early-onset Charcot- Marie-Tooth (CMT) disease. Methods Motor neurons were differentiated from induced pluripotent stem cells of a patient with early- onset CMT carrying a novel homozygous nonsense mutation in NEFL. Quantitative PCR, protein analytics, immunocytochemistry, electron microscopy, and single-cell transcriptomics were used to investigate patient and control neurons. Results We show that the recessive nonsense mutation causes a nearly total loss of NEFL messenger RNA (mRNA), leading to the complete absence of NEFL protein in patient’s cultured neurons. Yet the cultured neurons were able to differentiate and form neuronal networks and neuro- filaments. Single-neuron gene expression fingerprinting pinpointed NEFL as the most down- regulated gene in the patient neurons and provided data of intermediate filament transcript abundancy and dynamics in cultured neurons. Blocking of nonsense-mediated decay partially rescued the loss of NEFL mRNA. Conclusions The strict neuronal specificity of neurofilament has hindered the mechanistic studies of re- cessive NEFL nonsense mutations. Here, we show that such mutation leads to the absence of NEFL, causing childhood-onset neuropathy through a loss-of-function mechanism.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS
    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Supplementary Table 3
    Supplemental Table 1 M e13 ∆∆Ct e13 M e15 ∆∆Ct e15 chromogranin A -3,26 (9,6 ↓ ) -6,29 (78 ↓ ) -2,56 (5,9 ↓ ) -6,57 (95 ↓ ) crystallin, beta A2 -0,95 (1,9 ↓ ) -4,57 (24 ↓ ) -1,82 (3,5 ↓ ) -4 (16 ↓ ) cyclin-dependent kinase inhibitor 1A (P21) -1,15 (2,2 ↓ ) -1,41 (2,7 ↓ ) -0,36 (1,3 ↓ ) 0,29 (1,2 ↑ ) cytochrome P450, family 4, subfamily b, polypeptide 1 -0,68 (1,6 ↓ ) 0,16 (1,1 ↑ ) -0,56 (1,5 ↓ ) -0,08 (1,1 ↓ ) myelin transcription factor 1 -1,28 (2,4 ↓ ) -2,62 (6,1 ↓ ) -1,46 (2,8 ↓ ) -3,59 (12 ↓ ) neurogenic differentiation 2 -0,06 (1,0 → ) NA -1,34 (2,5 ↓ ) NA neuronatin 0,14 (1,1 ↑ ) 0,12 (1,1 ↑ ) -0,79 (1,7 ↓ ) -2,02 (4,1 ↓ ) protocadherin 21 -1,62 (3,1 ↓ ) -5,71 (52 ↓ ) -1,77 (3,4 ↓ ) -6,41 (85 ↓ ) regulated endocrine-specific protein 18 -2,1 (4,3 ↓ ) -4,73 (27 ↓ ) -1,55 (2,9 ↓ ) -5,09 (34 ↓ ) retinol binding protein 4, plasma -1,68 (3,2 ↓ ) -1,52 (2,9 ↓ ) -1,53 (2,9 ↓ ) -2,15 (4,4 ↓ ) rhomboid, veinlet-like 4 (Drosophila) -1,14 (2,2 ↓ ) -0,29 (1,2 ↓ ) -1,09 (2,1 ↓ ) -0,58 (1,5 ↓ ) sestrin 2 -0,78 (1,7 ↓ ) -0,84 (1,8 ↓ ) -0,67 (1,6 ↓ ) -0,61 (1,5 ↓ ) synaptotagmin 13 -1,63 (3,1 ↓ ) -2,59 (6,0 ↓ ) -1,77 (3,4 ↓ ) -2,71 (6,5 ↓ ) t-complex protein 11 -0,48 (1,4 ↓ ) -1,35 (2,5 ↓ ) -0,68 (1,6 ↓ ) -2,83 (7,1 ↓ ) -0,62 (1,5 ↓ ) -0,76 (1,7 ↓ ) transmembrane 4 superfamily member 2 -0,29 (1,2 ↓ ) -0,55 (1,5 ↓ ) -0,67 (1,6 ↓ ) -0,38 (1,3 ↓ ) 2510004L01Rik -0,7 (1,6 ↓ ) -1,58 (3,0 ↓ ) -0,07 (1,0 → ) 0,16 (1,1 ↑ ) C81234 -3,12 (8,7 ↓ ) -7,75 (215 ↓ ) -2,29 (4,9 ↓ ) -4,86 (29 ↓ ) Insulin 2 NM -9,89 (948 ↓ ) NM -14,2 (18820 ↓ ) Neurogenin 3 NM NA
    [Show full text]
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • The Correlation of Keratin Expression with In-Vitro Epithelial Cell Line Differentiation
    The correlation of keratin expression with in-vitro epithelial cell line differentiation Deeqo Aden Thesis submitted to the University of London for Degree of Master of Philosophy (MPhil) Supervisors: Professor Ian. C. Mackenzie Professor Farida Fortune Centre for Clinical and Diagnostic Oral Science Barts and The London School of Medicine and Dentistry Queen Mary, University of London 2009 Contents Content pages ……………………………………………………………………......2 Abstract………………………………………………………………………….........6 Acknowledgements and Declaration……………………………………………...…7 List of Figures…………………………………………………………………………8 List of Tables………………………………………………………………………...12 Abbreviations….………………………………………………………………..…...14 Chapter 1: Literature review 16 1.1 Structure and function of the Oral Mucosa……………..…………….…..............17 1.2 Maintenance of the oral cavity...……………………………………….................20 1.2.1 Environmental Factors which damage the Oral Mucosa………. ….…………..21 1.3 Structure and function of the Oral Mucosa ………………...….……….………...21 1.3.1 Skin Barrier Formation………………………………………………….……...22 1.4 Comparison of Oral Mucosa and Skin…………………………………….……...24 1.5 Developmental and Experimental Models used in Oral mucosa and Skin...……..28 1.6 Keratinocytes…………………………………………………….….....................29 1.6.1 Desmosomes…………………………………………….…...............................29 1.6.2 Hemidesmosomes……………………………………….…...............................30 1.6.3 Tight Junctions………………………….……………….…...............................32 1.6.4 Gap Junctions………………………….……………….….................................32
    [Show full text]